Myc-oncogene Inactivating Effect by Proline Rich Polypeptide (PRP-1) in Chondrosarcoma JJ012 Cells

被引:15
作者
Galoian, Karina [1 ]
Scully, Sean [2 ]
Galoyan, Armen [3 ]
机构
[1] Univ Miami, Miller Sch Med, Dept Orthoped, Miami, FL 33136 USA
[2] Univ Miami Hosp, Miller Sch Med, Dept Orthoped, Miami, FL 33136 USA
[3] Natl Acad Sci, Inst Biochem, Yerevan 0014, Armenia
关键词
Proline rich polypeptide; Chondrosarcoma; Myc oncogene; Hypothalamic neuropeptides; Cancer; CANCER;
D O I
10.1007/s11064-008-9794-6
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Proline rich polypeptide (PRP-1) produced by NPV and NSO cells is released into the general circulation and exerts its effect on the activity of immunocompetent and neuronal cells. PRP-1 is a unique regulator of hematopoiesis, stimulator of bone-marrow hematogenesis. Taking into consideration our preliminary data on antitumor and unique diverse biological properties of PRP-1 previously described by Galoyan et al., we proceeded with investigation of the PRP-1 effect on chondrosarcoma, the second most common malignancy in bone, which tends to be locally invasive and then metastatic. Currently it does not have any effective treatment and does not respond either to radiation or chemotherapy, leaving surgical resection as the only option. Our experimental results of PRP-1 action on human chondrosarcoma JJ012 cells demonstrated inactivation, abolishment of Myc oncogene activity usually upregulated in chondrosarcoma cells and other malignancies. The fact that addition of PRP-1 caused drastic inactivation of Myc-luc response element to the control level in human chondrosarcoma JJ012 cell line prompts to investigate further this neuropeptides powerful antioncogenic potential, opening up possibilities to consider PRP-1 as a potential therapeutic tool for chondrosarcoma treatment.
引用
收藏
页码:379 / 385
页数:7
相关论文
共 23 条
[1]   MOLECULAR THEMES IN ONCOGENESIS [J].
BISHOP, JM .
CELL, 1991, 64 (02) :235-248
[2]   Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the philadelphia chromosome. [J].
Druker, BJ ;
Sawyers, CL ;
Kantarjian, H ;
Resta, DJ ;
Reese, SF ;
Ford, JM ;
Capdeville, R ;
Talpaz, M .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1038-1042
[3]   Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. [J].
Druker, BJ ;
Talpaz, M ;
Resta, DJ ;
Peng, B ;
Buchdunger, E ;
Ford, JM ;
Lydon, NB ;
Kantarjian, H ;
Capdeville, R ;
Ohno-Jones, S ;
Sawyers, CL .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1031-1037
[4]   Cancer revoked: oncogenes as therapeutic targets [J].
Felsher, DW .
NATURE REVIEWS CANCER, 2003, 3 (05) :375-380
[5]   Pharmacological inactivation of MYC for the treatment of cancer [J].
Felsher, DW ;
Bradon, N .
DRUG NEWS & PERSPECTIVES, 2003, 16 (06) :370-374
[6]   2-methoxyestradiol induces apoptosis and cell cycle arrest in human chondrosarcoma cells [J].
Fong, Yi-Chin ;
Yang, Wei-Hong ;
Hsu, Sheng-Feng ;
Hsu, Horng-Chaung ;
Tseng, Kuo-Fung ;
Hsu, Chin-Jung ;
Lee, Chun-Yi ;
Scully, Sean P. .
JOURNAL OF ORTHOPAEDIC RESEARCH, 2007, 25 (08) :1106-1114
[7]   DEDIFFERENTIATED CHONDROSARCOMA - A REPORT OF THE CLINICOPATHOLOGICAL FEATURES AND TREATMENT OF 78 CASES [J].
FRASSICA, FJ ;
UNNI, KK ;
BEABOUT, JW ;
SIM, FH .
JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME, 1986, 68A (08) :1197-1205
[8]  
Galoian KA, 2007, EXP BIOL MED, V232, P515
[9]   Neurochemistry of brain neuroendocrine immune system: Signal molecules [J].
Galoyan, A .
NEUROCHEMICAL RESEARCH, 2000, 25 (9-10) :1343-1355
[10]   Treatment and prophylaxis of anthrax by new neurosecretory cytokines [J].
Galoyan, A. A. ;
Grigoryan, S. L. ;
Badalyan, K. V. .
NEUROCHEMICAL RESEARCH, 2006, 31 (06) :795-803